# OMAHA-003 (opevesostat): what clinicians are saying

> 34 statements from 9 sources (1 podcast, 1 video, 6 posts, 1 paper), 7 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 14, 2026.

## Report

- Trial: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
- NCT ID: NCT06136624
- Registry: https://clinicaltrials.gov/study/NCT06136624
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: opevesostat
- Indication: mCRPC after NHA and taxane-based chemotherapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-14 UTC
- Last checked: 2026-11-14 UTC
- Release hash: a099a483e7479ccc88bfeeceb58bbf274830d7703e1ff5cea08b41db4a688c20

## Counts

- Commentary sources screened: 22
- Sources cited by verified statements: 9
- Verified statements: 34
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 7
- Findings: 2
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Speakers cited: 5
- Cited speakers with a verified identity: 4
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For OMAHA-003, a medical oncologist described in the source as involved in the trial considers glucocorticoid and mineralocorticoid supplementation necessary because steroid production is blocked. They and a urologist see a rationale for reducing hormones that can activate mutated AR, but AR-LBD status is not established as a treatment-selection rule. Clinical benefit and comparative safety cannot be judged from these statements.

## Findings (titles)

- F1. Speakers describe adrenal hormone replacement as essential to the opevesostat strategy
  - 4 statements from 2 speakers in 4 sources, 2 of them podcasts or videos.
- F2. One speaker and one X account see a mutation-based rationale for upstream steroid suppression
  - 8 statements from 2 speakers in 5 sources, 1 of them a podcast or video.

The full report also has 4 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 4 | 4 | 4 | 2 | 2 |
| F2 | 8 | 8 | 5 | 2 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 3 | 0 | 0 | 0 | 1 | 5 | 0 | 1 post or article, 2 podcasts and video, 1 publication |
| F2 | 4 | 0 | 0 | 0 | 4 | 9 | 0 | 3 posts and articles, 1 podcast or video, 1 publication |

### Trial dimensions

- Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants: no finding draws on it directly
- Primary endpoint: OS in AR LBD Mutation-Negative Participants: no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: no finding draws on it directly
- The comparison: F2 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 2 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 9 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 5 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

7 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants | discussed | 1 | 1 |
| Primary endpoint: OS in AR LBD Mutation-Negative Participants | discussed | 1 | 1 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 3 | 3 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 3 | 2 |
| Safety and tolerability | discussed | 3 | 3 |
| Design and conduct | discussed | 4 | 2 |
| AR-LBD resistance, steroid ligands and ctDNA work-up | discussed | 9 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 12 statements · 35%** (from 2 videos and episodes · about 6 per source) | | | |
| YouTube | 8 | 1 | 1 |
| Podcasts | 4 | 1 | 1 |
| **Posts · 7 statements · 21%** (from 6 posts · about 1 per source) | | | |
| X threads | 4 | 5 | 19 |
| LinkedIn posts | 3 | 1 | 1 |
| **Primary sources · 15 statements · 44%** (cited for context, not screened · from 1 source · about 15 per source) | | | |
| Publications (primary source, cited for context) | 15 | 1 | not screened |

- Screened window: 2024-03-01 to 2026-11-06
- Cited window: 2025-04-30 to 2026-10-23
- Retrieved: 2026-11-14

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
- Registry: NCT06136624 (https://clinicaltrials.gov/study/NCT06136624)
- Study IDs: 5684-003 · 2023-504899-25-00 (EU CT) · MK-5684-003 (MSD) · jRCT2031240029 (Japan Registry of Clinical Trials (jRCT)) · U1111-1287-5304 (UTN)
- Sponsor: Merck Sharp & Dohme LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 1,310 (estimated)
- Start: 2023-12-31 (actual)
- Primary completion: 2028-11-30 (estimated)
- Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants (Up to ~54 months)
- Primary endpoint: OS in AR LBD Mutation-Negative Participants (Up to ~54 months)
- Intervention: Opevesostat (drug)
- Intervention: Abiraterone acetate (drug)
- Intervention: Enzalutamide (drug)
- Intervention: Hydrocortisone (drug)
- Intervention: Fludrocortisone acetate (drug)
- Intervention: Prednisone (drug)
- Intervention: Dexamethasone (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on efficacy and toxicity of adding mevrometostat to enzalutamide after abiraterone in metastatic castration-resistant prostate cancer.
- 6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 23 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, organizational relays and repeated posts by one account must not be counted as additional independent clinical assessments.
- Coverage centers on the trial identifier and known names. Discussion using unnamed references, different wording or other transcription variants may be missing.
- Earlier CYPIDES activity and planned OMAHA-003 methods do not establish OMAHA-003 efficacy, survival benefit or comparative safety.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A separate protocol document was not available from ClinicalTrials.gov; the published design report supplies methodological context rather than a complete protocol.
- Regulatory coverage is incomplete, and no exact opevesostat label was identified. No approved indication or regulatory treatment role can be concluded from this report.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-14 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-14 UTC. No changes.

## Offer

- Size: Focused · 34 verified statements · 7 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (4 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/omaha-003-nct06136624
- Agents: POST https://www.erudio.com/api/orders with {"report": "omaha-003-nct06136624", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=omaha-003-nct06136624

## Cite

Erudio Health. OMAHA-003 (NCT06136624): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 14, 2026. https://www.erudio.com/reports/omaha-003-nct06136624

## Questions

### How much does the OMAHA-003 report cost?

One edition costs $750 (Focused · 34 verified statements · 7 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the OMAHA-003 report cover?

34 statements from 9 sources (1 podcast, 1 video, 6 posts, 1 paper), 7 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 14, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the OMAHA-003 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "omaha-003-nct06136624" }) previews it and create_order({ "report": "omaha-003-nct06136624", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the OMAHA-003 report?

Edition 1 (version 1.0.0), accepted Nov 14, 2026 UTC; last checked for new commentary Nov 14, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/omaha-003-nct06136624.json
- Markdown: https://www.erudio.com/reports/omaha-003-nct06136624.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/omaha-003-nct06136624/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "omaha-003-nct06136624"}`